Lead Product(s): Undisclosed
Therapeutic Area: Immunology
Highest Development Status: Discovery Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020
In this joint reaserch collaboration, Ryvu is responsible for early drug discovery. Galapagos will have an exclusive option to license IP developed by Ryvu.